Vericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing Facility
Rhea-AI Summary
Vericel (NASDAQ:VCEL) announced FDA approval to commercially manufacture MACI at its new Burlington, Massachusetts cell therapy facility. The approval permits commercial production to begin in Q2 2026, increases manufacturing capacity to support long-term growth, and enables potential MACI commercialization outside the U.S.
This milestone strengthens the company’s supply chain and positions Vericel to scale MACI production to meet rising demand for restorative cartilage repair therapies.
Positive
- FDA approval for commercial MACI manufacturing
- Commercial production scheduled to start in Q2 2026
- Increased manufacturing capacity to support long-term growth
- Enables potential MACI commercialization outside the U.S.
- New state-of-the-art facility located in Burlington, MA
Negative
- Commercial launch timing depends on successful scale-up in Q2 2026
News Market Reaction – VCEL
In the Mar 4 session, VCEL gained 1.66%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Fda approval Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 26 | MACI Arthro approval | Positive | +1.3% | FDA approval of MACI Arthro, expanding label to arthroscopic procedures. |
| Aug 15 | NexoBrid pediatric nod | Positive | +0.3% | FDA approval expanding NexoBrid use to pediatric severe burn patients. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior FDA approvals for Vericel have led to modest but positive next-day moves, indicating historically constructive reactions to regulatory milestones.
Over the past six months, Vericel has delivered strong fundamentals, with $276.3M in 2025 revenue and $239.5M from MACI, alongside record gross margins and solid cash. Tag-specific history shows two prior FDA approval milestones for MACI Arthro and NexoBrid, both followed by small positive price reactions. Today’s FDA approval for the Burlington manufacturing facility extends this pattern of regulatory progress supporting the MACI and burn-care franchises.
Key Terms
fda regulatory
autologous cultured chondrocytes medical
porcine collagen membrane medical
cell therapy medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company Achieves Significant Regulatory and Operational Milestone
Substantially Increases Manufacturing Capacity to Support Long-Term Growth
Enables Potential MACI Commercialization Outside of the U.S.
CAMBRIDGE, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for MACI® (autologous cultured chondrocytes on porcine collagen membrane) commercial manufacturing at its state-of-the-art cell therapy manufacturing facility in Burlington, Massachusetts. The approval enables Vericel to begin commercial production of MACI at its new facility in the second quarter of 2026, positioning the Company to expand capacity to meet increasing demand for its restorative cartilage repair product and potentially commercialize MACI outside of the United States.
“This FDA approval reflects a major achievement for Vericel and underscores the Company’s operational and scientific expertise in complex cell therapy manufacturing,” said Nick Colangelo, President and Chief Executive Officer of Vericel. “Bringing our Burlington facility online for commercial MACI production strengthens our supply chain and supports our mission to deliver innovative, high-quality therapies to patients. We look forward to building on this foundation as we continue to scale our business and create long-term value for patients and shareholders.”
About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to
Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2026 Vericel Corporation. All rights reserved.
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements are subject to risks and uncertainties such as those described in Vericel’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411
